Theradaptive Receives FDA Approval for Pivotal Phase 3 Trial of OsteoAdapt SP in Spinal Fusion

Key Takeaways

• FDA grants Theradaptive approval to advance OsteoAdapt SP to pivotal Phase 3 clinical trial for spinal fusion procedures
• OASIS trial represents critical milestone for next-generation bone regeneration therapy targeting degenerative spinal diseases
• Approval enables company to move closer to potential commercialization of targeted protein therapeutic for tissue regeneration

---

FREDERICK, Md., April 30, 2026 — Theradaptive, Inc., a clinical-stage biotechnology company developing targeted protein therapeutics for tissue regeneration, announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s advancement of its OASIS trial to a pivotal Phase 3 study evaluating OsteoAdapt SP in spinal fusion procedures.

Breakthrough in Bone Regeneration Therapy

The FDA authorization represents a significant regulatory milestone for Theradaptive’s innovative approach to treating degenerative spinal diseases. OsteoAdapt SP is designed as a next-generation bone regeneration therapy that could potentially transform treatment outcomes for patients requiring spinal fusion surgery.

Spinal fusion procedures are commonly performed to treat various degenerative spinal conditions, including disc degeneration, spinal stenosis, and spondylolisthesis. Current treatment options often rely on bone grafts or synthetic materials, which can have limitations in terms of integration and healing time.

Market Impact and Clinical Significance

The advancement to Phase 3 represents the final stage of clinical testing before potential FDA approval for commercial use. This pivotal trial will evaluate the safety and efficacy of OsteoAdapt SP compared to standard treatment approaches in a larger patient population.

Theradaptive’s targeted protein therapeutic approach aims to enhance the body’s natural bone healing processes, potentially offering improved outcomes for patients undergoing spinal fusion procedures. The therapy’s mechanism focuses on stimulating bone regeneration at the cellular level through precisely targeted protein delivery.

Next Steps and Timeline

The OASIS Phase 3 trial is expected to enroll patients across multiple clinical sites, with results anticipated to support a potential Biologics License Application (BLA) submission to the FDA. The company has not yet disclosed specific enrollment targets or estimated completion timelines for the pivotal study.

This regulatory advancement positions Theradaptive among a select group of companies developing innovative regenerative medicine solutions for orthopedic applications, particularly in the growing spinal fusion market.

---

Frequently Asked Questions

What does this FDA approval mean for patients with spinal conditions?

This approval allows Theradaptive to conduct the final Phase 3 clinical trial of OsteoAdapt SP, bringing the potential treatment one step closer to market availability for patients requiring spinal fusion surgery.

When will OsteoAdapt SP be available to patients?

OsteoAdapt SP is still in clinical trials. If the Phase 3 trial is successful, Theradaptive would need to submit a Biologics License Application to the FDA, which could take several more years before potential market approval.

How does OsteoAdapt SP differ from current spinal fusion treatments?

OsteoAdapt SP is designed as a targeted protein therapeutic that aims to enhance the body’s natural bone healing processes, potentially offering improved outcomes compared to traditional bone grafts or synthetic materials currently used in spinal fusion procedures.